摘要
在过去的几十年中,证据积累表明副交感神经支配调节肝损伤和再生。肝脏通过迷走神经获得其副交感神经输入。在动物模型中,经常使用迷走神经刺激和横切来确定副交感神经输入对肝损伤反应的影响。这种策略对参与调节肝损伤的神经元机制提供了有限的理解。迷走神经的肝分支释放乙酰胆碱(ACh),其激活肝细胞中的毒蕈碱和烟碱受体以及非实质细胞以调节细胞功能。此外,迷走神经释放其他神经递质,如血管活性肠肽(VIP),它也调节肝脏损伤反应和血流动力学。因此,我们对利用迷走神经活动的模型中肝脏损伤后神经元调节的理解仍然有限。基因沉默技术和受体活性的药理操作不仅提高了我们对特定胆碱能受体作用的理解,而且还阐明了各种肝细胞亚群在调节肝损伤反应中的作用。随着器官和细胞特异性转基因小鼠的出现,我们对肝损伤神经调节的理解可能会进一步改善。本综述提供了对肝损伤胆碱能调节的最新理解,并指出了治疗肝损伤的潜在治疗靶点。
关键词: 肝损伤,副交感神经系统,毒蕈碱受体,烟碱受体。
图形摘要
Current Drug Targets
Title:Targeting Cholinergic System to Modulate Liver Injury
Volume: 19 Issue: 8
关键词: 肝损伤,副交感神经系统,毒蕈碱受体,烟碱受体。
摘要: Over the past few decades, evidence accumulated to indicate that parasympathetic innervation regulates liver injury and regeneration. Liver derives its parasympathetic input via vagus nerve. In animal models, vagus nerve stimulation and transection are frequently used to determine the impact of parasympathetic input on liver injury responses. Such strategies provide limited understanding of postneuronal mechanisms involved in the regulation of liver injury. The hepatic branch of vagus nerve releases acetylcholine (ACh), which activates muscarinic and nicotinic receptors in hepatocytes as well as non-parenchymal cells to modulate cellular functions. Moreover, vagus nerve releases other neurotransmitters such as vasoactive intestinal peptide (VIP), which also modulates liver injury responses and hemodynamics. Therefore, our understanding of the post-neuronal modulation of liver injury in models utilizing vagus nerve activity remains limited. Gene-silencing technologies and pharmacological manipulation of receptor activity have not only improved our understanding of the role of specific cholinergic receptors but also elucidated the role of various liver cell sub-populations in modulating liver injury response. With advent of organ- and cell-specific transgenic mice, our understanding of neural regulation of liver injury is likely to improve further. This review comprehensively provides current understanding of cholinergic regulation of liver injury, and points to potential therapeutic targets to treat liver injury.
Export Options
About this article
Cite this article as:
Targeting Cholinergic System to Modulate Liver Injury, Current Drug Targets 2018; 19 (8) . https://dx.doi.org/10.2174/1389450118666170619090219
DOI https://dx.doi.org/10.2174/1389450118666170619090219 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Mesenteric Venous Thrombosis in Early Pregnancy
Current Women`s Health Reviews Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Modulation of PMN-Endothelial Cells Interactions by Cyclic Nucleotides
Current Pharmaceutical Design Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmaceutical Aspects of Hemoglobin-Based Oxygen Carriers
Current Drug Delivery